UK Inquiry Into ‘Unfair’ Orkambi Pricing Risks Pricing Confidentiality

 
• By Francesca Bruce

The UK government has criticized Vertex for the company’s approach to pricing its cystic fibrosis drug Orkambi. In the meantime, a parliamentary inquiry that could expose sensitive pricing details moves forward.

Cystic Fibrosis, Medical Concept with Pills, Injections and Syringe. Cystic Fibrosis - Printed Diagnosis with Blurred Text. 3D Render.
An Inquiry into the pricing of cystic fibrosis drug Orkambi Could Compromise Pricing Confidentiality

More from Europe

More from Geography